Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants With Moderately to Severely Active Crohn’s Disease: Results From the Phase 3 GRAVITI Study
Ailsa Hart(St Mark's Hospital), Bruce E. Sands(Icahn School of Medicine at Mount Sinai), Ursula Seidler(Medizinische Hochschule Hannover), Tadakazu Hisamatsu(Kyorin University), Remo Panaccione, Silvio Danese(IRCCS Ospedale San Raffaele), Geert D’Haens(Amsterdam University Medical Centers), Mobolaji Olurinde(Johnson & Johnson (United States)), Jewel Johanns(Janssen (United States)), Flávio Steinwurz(Hospital Israelita Albert Einstein), Zijiang Yang(Xi'an Jiaotong University), Natalie A. Terry(Janssen (United States)), Yuhua Wang(Johnson & Johnson (United States)), Qian Cao(Sir Run Run Shaw Hospital), Aparna Sahoo(Otsuka (United States)), Marion Vetter(Janssen (United States)), Jacqueline Yee(Johnson & Johnson (United States)), Chenglong Han(Janssen (United States)), Timothy E. Ritter(Unknown)
Cited by 46
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k